羧甲司坦片联合沙丁胺醇气雾剂治疗慢性阻塞性肺疾病患者的临床研究OACSTPCD
Clinical trial of carbocisteine tablets combined with salbutamol aerosol in the treatment of patients with chronic obstructive pulmonary disease
目的 研究羧甲司坦片联合沙丁胺醇气雾剂治疗慢性阻塞性肺疾病(COPD)患者的临床疗效,以及对患者肺功能、氧化应激指标的影响.方法 将COPD患者分为试验组和对照组.对照组接受沙丁胺醇气雾剂治疗,试验组在对照组的基础上给予羧甲司坦片,每次0.5 g,每天3次,口服治疗3个月.比较2组患者的肺功能情况、氧化应激指标、慢性阻塞性肺疾病自我评估测试情况(CAT)及血清炎症因子水平.结果 治疗后,试验组和对照组的第1秒用力呼气量占用力肺活量百分比(FEV1/FVC)分别为(83.26±3.88)％和(75.12±3.87)％,用力肺活量(FVC)分别为(3.67±0.31)和(3.11±0.22)L,FEV1分别为(1.65±0.17)和(1.43±0.11)L·s-1,总抗氧化能力(T-AOC)分别为(36.81±3.09)和(23.25±2.10)U·mL-1,谷胱甘肽过氧化物酶(GPX)分别为(73.49±3.45)和(53.13±3.55)nmol·L-1,丙二醛(MDA)分别为(12.74±1.14)和(10.09±1.10)nmol·mL-1,超氧化物歧化酶(SOD)水平分别为(328.30±16.96)和(462.44±17.73)U·mL-1,CAT 主观指标分别为(11.04±2.00)和(18.03±3.23)分,运动指标分数分别为(4.16±1.80)和(6.66±1.76)分,血清白细胞介素-17(IL-17)分别为(29.39±2.38)和(40.90±2.80)pg·mL-1,肿瘤坏死因子-α(TNF-α)分别为(31.96±2.04)和(40.04±2.57)pg·mL-1,高迁移率族蛋白1(HMGB1)水平分别为(41.50±3.03)和(72.23±4.63)pg·mL-1,在统计学上差异均有统计学意义(均P＜0.05).试验组和对照组药物不良反应发生率分别为10.53％和20.00％,在统计学上差异无统计学意义(P＞0.05).结论 在COPD临床治疗中联合应用羧甲司坦片、沙丁胺醇气雾剂能有效提高临床疗效,降低炎症反应,改善患者肺功能通气情况,减轻氧化应激反应.
Objective To study the clinical efficacy of carbocisteine tablets combined with salbutamol aerosol in the treatment of chronic obstructive pulmonary disease(COPD),and its effect on lung function and oxidative stress indexes.Methods COPD patients were divided into treatment group and control group.The control group was treated with salbutamol aerosol,and the treatment group was treated with carbocisteine tablets on the basis of the control group,0.5 g each time,3 times a day for 3 months.The pulmonary function,oxidative stress index,COPD self-assessment test(CAT)and serum inflammatory factor levels were compared between the two groups.Results After treatment,the forced expiratory volume in one second/forced vital capacity(FEV1/FVC)of the treatment group and the control group were(83.26±3.88)％and(75.12±3.87)％;forced vital capacity(FVC)were(3.67±0.31)and(3.11±0.22)L;forced expiratory volume in one second(FEV1)were(1.65±0.17)and(1.43±0.11)L·s-1;total antioxidant capacity(T-AOC)were(36.81±3.09)and(23.25±2.10)U·mL-1;glutathione peroxidase(GPX)were(73.49±3.45)and(53.13±3.55)nmol·L-1;malondialdehyde(MDA)were(12.74±1.14)and(10.09±1.10)nmol·mL-1;superoxide dismutase(SOD)levels were(328.30±16.96)and(462.44±17.73)U·mL-1;the subjective scores of CAT were 11.04±2.00 and 18.03±3.23;the motor index scores were 4.16±1.80 and 6.66±1.76;the serum interleukin-17(IL-17)levels were(29.39±2.38)and(40.90±2.80)pg·mL-1;tumor necrosis factor-α(TNF-α)were(31.96±2.04)and(40.04±2.57)pg·mL-1;the high-mobilitygroup box 1(HMGB1)levels were(41.50±3.03)and(72.23±4.63)pg·mL-1;the differences were all statistically significant(all P＜0.05).The incidence of adverse drug reactions in the treatment group and the control group was 10.53％and 20.00％,respectively,and the difference was not statistically significant(P＞0.05).Conclusion The combination of carbocisteine tablets and salbutamol aerosol in the clinical treatment of COPD can effectively improve the clinical efficacy,reduce inflammatory response,improve pulmonary function ventilation,and reduce oxidative stress.
李敬;王坤
青岛市市立医院西院区、青岛市老年病医院急诊科,山东青岛 266300青岛市胶州中心医院胸外科,山东青岛 266300
药学
沙丁胺醇气雾剂羧甲司坦片慢性阻塞性肺疾病氧化应激反应
salbutamol aerosolcarbocisteine tabletchronic obstructive pulmonary diseaseoxidative stress response
《中国临床药理学杂志》 2024 (002)
155-159 / 5
评论